sutrobio.com (STRO): Price-to-Projected Revenue Ratio

STRO (Sutro Biopharma Inc.) - company brandmark

Sutro Biopharma, Inc. (STRO) is optimizing costs through the automation of its California plant. GURU.Markets provides this chart based on the forward price-to-sales ratio, where the current parameter is 3.50. Business revenues are based on the sale of its antibody-drug conjugate platform. Pipeline development relies on strategic R&D alliances with industry behemoths to co-fund clinical trials.

STRO Sutro Biopharma Inc.: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Sutro Biopharma, Inc (STRO)

- stock price and consensus target price:
Stock Quotes Sutro Biopharma|STRO - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Sutro Biopharma, Inc|STRO - Business Value
- book value of equity indicators:
Net Assets per Single Share Sutro Biopharma|STRO - Total Stockholders' Equity|Market Cap to Net Assets Ratio sutrobio.com|STRO - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Sutro Biopharma, Inc.|STRO - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Sutro Biopharma, Inc.|STRO - Aggregate Debt Obligations|Debts to Book Capitalization Sutro Biopharma, Inc|STRO - Long-Term Debt|Company Short-Term Debt Sutro Biopharma|Quick Ratio sutrobio.com
- business earnings and investment ratios data:
STRO - Net Profit|Expected Profit Sutro Biopharma, Inc.|STRO - Market Cap to Net Income|Projected Price to Earnings Sutro Bio|STRO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sutro Biopharma, Inc|STRO - Operating income before deduction of amortization|Net earnings per share for the last 12 months Sutro Biopharma|STRO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months sutrobio.com|STRO - Net earnings per one share growth for the current year|Net earnings per share growth forecast for next year Sutro Biopharma, Inc.
- revenue and sales details:
STRO - Company Sales Revenue|Company Projected Revenue Sutro Biopharma|STRO - Price to Sales|Forward Price-to-Revenue Multiple Sutro Biopharma, Inc
Summary company analysis:Sutro Biopharma STRO
Manufactured products of Sutro Biopharma, Inc

Monetization of the antibody conjugate platform through contracts with pharma behemoths establishes the base of expected revenues, which are compared against the current market capitalization of Sutro Biopharma (STRO) when calculating the business's forward P/S ratio. This indicator measures the premium investors are willing to pay per unit of future revenue, allowing an analysis of the forward P/S to distinguish fundamental undervaluation from temporary market volatility.

Competitor analysis

ImmunityBio - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Holdings IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (Arcus Corp) - Market Cap to Projected Revenue|Zymeworks Inc. (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio tangotx.com (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune Group, Inc.)|Forward Price to Sales LYEL|Innate Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology, Inc.|cgen.com (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech Inc. - Forward Price to Sales|INKT (MiNK Therapeutics, Inc.) - Forward P/S Multiple|Forward P/S Multiple Werewolf|Price-to-Projected Revenue Ratio Immix Biopharma, Inc. (IMMX)|ALXO: Future Price to Revenue|Cue Biopharma, Inc. - Forward Price-to-Revenue Multiple|PDS Biotech (PDSB) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio MAIABiotech.com MAIA|LIMN (Liminatus Pharma LLC) - Forward Price-to-Revenue Multiple|LAVA Therapeutics (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|LPTX (Leap Tx) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Intensity Therapeutics (INTS)|SNSE (senseibio.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Theriva Biologics TOVX|Gritstone bio Inc. (GRTS) - Market Cap to Future Revenue Ratio|KA: Forward Price-to-Revenue Multiple|Forward Price to Sales NEXI (NexImmune Corporation)|TSBX: Forward P/S Multiple|VCNX (vaccinex.com) - Price-to-Projected Revenue Ratio|HARP (Harpoon Therapeutics, Inc.) - Forward P/S Multiple